Mesothelin antibody protein fusions and methods of use

Details Mesothelin antibody protein fusions and methods of use Mesothelin antibody protein fusions and methods of use

2011-05-17

2011-05-17

Swartz, Rodney P. (Department: 1645)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S133100, C424S135100, C424S136100

Reexamination Certificate

active

07943133

ABSTRACT:
The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising a stress protein fused with an antibody binding protein in combination with an engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising an engineered antibody or fragment that binds specifically to mesothelin fused in frame with a biotin binding protein. The invention also provides fusion proteins comprising an engineered antibody or fragment, that binds to mesothelin, fused with an antibody binding protein. The invention also relates to methods of using fusion proteins of the invention to induce an immune response to mesothelin and to treat disease.

REFERENCES:
patent: 6338952 (2002-01-01), Young
patent: 7189396 (2007-03-01), Weisbart
patent: 2005/0221395 (2005-10-01), Zabrecky et al.
patent: 2009/0068184 (2009-03-01), Gelfand
patent: 2006/099141 (2006-09-01), None
patent: 2007/136892 (2007-11-01), None
S. Dubel et al., “Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)”, J. Immunol. Methods, 178(2), pp. 201-209 (1995). [Abstract only].
W. Ito et al., “Development of an Artificial Antibody System with Multiple Valency Using an Fv Fragment Fused to a Fragment of Protein A”, The Journal of Biological Chemistry, 268(27), pp. 20668-20675 (1993).
J. Goncalves et al., “Functional Neutralization of HIV-1 Vif Protein by Intracellular Immunization Inhibits Reverse and Viral Replication”, The Journal of Biological Chemistry, 277(35), pp. 32036-32045 (2002).
R. Hassan et al., “Mesothelin targeted cancer immunotherapy”, Eur. J. Cancer, 44(1), pp. 46-53 (2008).
J.E. Hansen et al., “Antibody-Mediated Transduction of Therapeutic Proteins into Living Cells”, The Scientific World Journal, vol. 5, pp. 782-788 (2005).
J.E. Hansen et al., “Antibody-mediated Hsp70 Protein Therapy”, Brain Research, vol. 1088, pp. 187-196 (2006).
B. Cochlovius et al., “Cure of Burkitt's Lymphoma in Servere Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 x CD19 Tandem Diabody, and CD28 Contimulation”, Cancer Research, vol. 60, pp. 4336-4341 (2000).
International Search Report and Written Opinion from PCT/US09/05991.

Affiliated with

Also associated with

Rating

Mesothelin antibody protein fusions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mesothelin antibody protein fusions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mesothelin antibody protein fusions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2622633